404 related articles for article (PubMed ID: 16110011)
1. Neurocognitive consequences of risk-adapted therapy for childhood medulloblastoma.
Mulhern RK; Palmer SL; Merchant TE; Wallace D; Kocak M; Brouwers P; Krull K; Chintagumpala M; Stargatt R; Ashley DM; Tyc VL; Kun L; Boyett J; Gajjar A
J Clin Oncol; 2005 Aug; 23(24):5511-9. PubMed ID: 16110011
[TBL] [Abstract][Full Text] [Related]
2. A prospective neurocognitive evaluation of children treated with additional chemotherapy and craniospinal irradiation following isolated central nervous system relapse in acute lymphoblastic leukemia.
Kumar P; Mulhern RK; Regine WF; Rivera GK; Kun LE
Int J Radiat Oncol Biol Phys; 1995 Feb; 31(3):561-6. PubMed ID: 7852120
[TBL] [Abstract][Full Text] [Related]
3. White matter lesions detected by magnetic resonance imaging after radiotherapy and high-dose chemotherapy in children with medulloblastoma or primitive neuroectodermal tumor.
Fouladi M; Chintagumpala M; Laningham FH; Ashley D; Kellie SJ; Langston JW; McCluggage CW; Woo S; Kocak M; Krull K; Kun LE; Mulhern RK; Gajjar A
J Clin Oncol; 2004 Nov; 22(22):4551-60. PubMed ID: 15542806
[TBL] [Abstract][Full Text] [Related]
4. Concurrent chemotherapy and reduced-dose cranial spinal irradiation followed by conformal posterior fossa tumor bed boost for average-risk medulloblastoma: efficacy and patterns of failure.
Douglas JG; Barker JL; Ellenbogen RG; Geyer JR
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1161-4. PubMed ID: 15001259
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic schedules influence the pattern of intellectual decline after irradiation of posterior fossa tumors.
Kieffer-Renaux V; Viguier D; Raquin MA; Laurent-Vannier A; Habrand JL; Dellatolas G; Kalifa C; Hartmann O; Grill J
Pediatr Blood Cancer; 2005 Nov; 45(6):814-9. PubMed ID: 15924360
[TBL] [Abstract][Full Text] [Related]
6. Online quality control, hyperfractionated radiotherapy alone and reduced boost volume for standard risk medulloblastoma: long-term results of MSFOP 98.
Carrie C; Grill J; Figarella-Branger D; Bernier V; Padovani L; Habrand JL; Benhassel M; Mege M; Mahé M; Quetin P; Maire JP; Baron MH; Clavere P; Chapet S; Maingon P; Alapetite C; Claude L; Laprie A; Dussart S
J Clin Oncol; 2009 Apr; 27(11):1879-83. PubMed ID: 19273707
[TBL] [Abstract][Full Text] [Related]
7. Patterns of failure using a conformal radiation therapy tumor bed boost for medulloblastoma.
Wolden SL; Dunkel IJ; Souweidane MM; Happersett L; Khakoo Y; Schupak K; Lyden D; Leibel SA
J Clin Oncol; 2003 Aug; 21(16):3079-83. PubMed ID: 12915597
[TBL] [Abstract][Full Text] [Related]
8. Endocrine outcomes for children with embryonal brain tumors after risk-adapted craniospinal and conformal primary-site irradiation and high-dose chemotherapy with stem-cell rescue on the SJMB-96 trial.
Laughton SJ; Merchant TE; Sklar CA; Kun LE; Fouladi M; Broniscer A; Morris EB; Sanders RP; Krasin MJ; Shelso J; Xiong Z; Wallace D; Gajjar A
J Clin Oncol; 2008 Mar; 26(7):1112-8. PubMed ID: 18309946
[TBL] [Abstract][Full Text] [Related]
9. A pilot study of preirradiation chemotherapy and 1800 cGy craniospinal irradiation in young children with medulloblastoma.
Jakacki RI; Feldman H; Jamison C; Boaz JC; Luerssen TG; Timmerman R
Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):531-6. PubMed ID: 15380589
[TBL] [Abstract][Full Text] [Related]
10. Multi-institution prospective trial of reduced-dose craniospinal irradiation (23.4 Gy) followed by conformal posterior fossa (36 Gy) and primary site irradiation (55.8 Gy) and dose-intensive chemotherapy for average-risk medulloblastoma.
Merchant TE; Kun LE; Krasin MJ; Wallace D; Chintagumpala MM; Woo SY; Ashley DM; Sexton M; Kellie SJ; Ahern V; Gajjar A
Int J Radiat Oncol Biol Phys; 2008 Mar; 70(3):782-7. PubMed ID: 17892918
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant chemotherapy after reduced craniospinal irradiation dose in children with average-risk medulloblastoma: a 5-year follow-up study.
Wahba HA; Abu-Hegazy M; Wasel Y; Ismail EI; Zidan AS
J BUON; 2013; 18(2):425-9. PubMed ID: 23818356
[TBL] [Abstract][Full Text] [Related]
12. Low-dose craniospinal irradiation and ifosfamide, cisplatin and etoposide for non-metastatic embryonal tumors in the central nervous system.
Yasuda K; Taguchi H; Sawamura Y; Ikeda J; Aoyama H; Fujieda K; Ishii N; Kashiwamura M; Iwasaki Y; Shirato H
Jpn J Clin Oncol; 2008 Jul; 38(7):486-92. PubMed ID: 18573848
[TBL] [Abstract][Full Text] [Related]
13. Intellectual impairment after treatment for medulloblastoma and astrocytoma in childhood: the Brazilian experience.
Hazin I; Dellatolas G; Garcia D; Pedrosa F; Pedrosa A
J Pediatr Hematol Oncol; 2011 Oct; 33(7):506-15. PubMed ID: 21941143
[TBL] [Abstract][Full Text] [Related]
14. No salvage using high-dose chemotherapy plus/minus reirradiation for relapsing previously irradiated medulloblastoma.
Massimino M; Gandola L; Spreafico F; Biassoni V; Luksch R; Collini P; Solero CN; Simonetti F; Pignoli E; Cefalo G; Poggi G; Modena P; Mariani L; Potepan P; Podda M; Casanova M; Pecori E; Acerno S; Ferrari A; Terenziani M; Meazza C; Polastri D; Ravagnani F; Fossati-Bellani F
Int J Radiat Oncol Biol Phys; 2009 Apr; 73(5):1358-63. PubMed ID: 19019566
[TBL] [Abstract][Full Text] [Related]
15. Longterm treatment results of childhood medulloblastoma by craniospinal irradiation in supine position.
Slampa P; Pavelka Z; Dusek L; Hynkova L; Sterba J; Ondrova B; Princ D; Novotny T; Kostakova S
Neoplasma; 2007; 54(1):62-7. PubMed ID: 17203894
[TBL] [Abstract][Full Text] [Related]
16. Developmental model relating white matter volume to neurocognitive deficits in pediatric brain tumor survivors.
Reddick WE; White HA; Glass JO; Wheeler GC; Thompson SJ; Gajjar A; Leigh L; Mulhern RK
Cancer; 2003 May; 97(10):2512-9. PubMed ID: 12733151
[TBL] [Abstract][Full Text] [Related]
17. Multivariate analysis of dissemination relapse of medulloblastoma and estimation of its time parameter for craniospinal irradiation.
Inakoshi H; Kayamori R; Tsuchida E; Sakai K; Shibamoto Y; Wakushima H; Ogawa Y; Kobayashi M; Obara T
Radiat Med; 2003; 21(1):37-45. PubMed ID: 12801142
[TBL] [Abstract][Full Text] [Related]
18. Hydrocephalus as a possible additional contributor to cognitive outcome in survivors of pediatric medulloblastoma.
Hardy KK; Bonner MJ; Willard VW; Watral MA; Gururangan S
Psychooncology; 2008 Nov; 17(11):1157-61. PubMed ID: 18636431
[TBL] [Abstract][Full Text] [Related]
19. Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma.
Packer RJ; Gajjar A; Vezina G; Rorke-Adams L; Burger PC; Robertson PL; Bayer L; LaFond D; Donahue BR; Marymont MH; Muraszko K; Langston J; Sposto R
J Clin Oncol; 2006 Sep; 24(25):4202-8. PubMed ID: 16943538
[TBL] [Abstract][Full Text] [Related]
20. Radiation dose to the lens during craniospinal irradiation-an improvement in proton radiotherapy technique.
Cochran DM; Yock TI; Adams JA; Tarbell NJ
Int J Radiat Oncol Biol Phys; 2008 Apr; 70(5):1336-42. PubMed ID: 18029111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
